Immune-based Therapies
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study
PloS One 2024 July 15 [Link] Jolien Van den Bossche, Maxime De Laere, Koen Deschepper, Paul Germonpré, Yvan Valcke, Jan Lamont, Barbara Stein, Kirsten Van Camp, Charlotte Germonpré, Griet Nijs, Ella Roelant, Sébastien Anguille, Eva Lion, Zwi Berneman Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with a very poor prognosis. Recently, immune checkpoint…
Read MoreCharacterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma
Scientific Reports 2024 July 10 [Link] Riki Okita, Tomoya Senoo, Yuka Mimura-Kimura, Yusuke Mimura, Tomoyuki Murakami, Eiji Ikeda, Masanori Okada, Hidetoshi Inokawa, Keisuke Aoe Abstract The clinical impact of soluble molecules in pleural effusion (PE) is unclear in patients with malignant pleural mesothelioma (MPM). In this single-center, retrospective, observational study, we assessed soluble forms of…
Read MoreMajor pathological response obtained after neoadjuvant chemotherapy combined with dual immunotherapy for malignant pleural mesothelioma: a case report
Translational Lung Cancer Research 2024 June 30 [Link] Yuchen Zhang, Guangyin Zhao, Chen Xu, Jie Gu, Di Ge Abstract Background: Malignant pleural mesothelioma (MPM) is a rare thoracic malignancy with high morbidity and mortality. A combination of systemic therapy and surgery may be a promising modality for the treatment of MPM, but evidence-based medicine is…
Read MoreComparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma
Oncotarget 2024 June 20 [Link] Kazuhiro Kitajima, Kozo Kuribayashi, Toshiyuki Minami, Hiroyuki Yokoyama, Akifumi Nakamura, Masaki Hashimoto, Takashi Kijima, Seiki Hasegawa, Hayato Kaida, Koichiro Yamakado Abstract Objectives: Results for malignant pleural mesothelioma (MPM) patients following first-line treatment with nivolumab plus ipilimumab obtained with immunotherapy-modified PERCIST (imPERCIST), shown by [18F]fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), and…
Read MoreDendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study
The Lancet Oncology 2024 June 4 [Link] Joachim G Aerts, Robert Belderbos, Paul Baas, Arnaud Scherpereel, Koen Bezemer, Ilona Enninga, Rob Meijer, Marcella Willemsen, Rossana Berardi, Dean Fennell, Rene Kerstens, Robin Cornelissen 2, Jan P van Meerbeeck Abstract Background: Dendritic cell immunotherapy has proven to be safe and induces an immune response in humans. We…
Read MoreComparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma
Thoracic Cancer 2024 June 5 [Link] Xuemei Zhang, Lele Chang, Qian Ma, Qian Zhang, Wansu Xu, Qingwei Li Abstract Background: This study aimed to investigate the effects of immune checkpoint inhibitors (ICIs) versus chemotherapy on the prognosis of real-world diffuse pleural mesothelioma patients in China. Methods: Clinical data of 90 patients with diffuse pleural mesothelioma…
Read MoreGenomic and T cell repertoire biomarkers associated with malignant mesothelioma survival
Thoracic Cancer 2024 May 27 [Link] Muwen Nie, Zhao Sun, Ningning Li, Liangrui Zhou, Shuchun Wang, Mingming Yuan, Rongrong Chen, Lin Zhao, Ji Li, Chunmei Bai Abstract Background: Malignant mesothelioma (MM) is an exceedingly rare tumor with poor prognosis due to the limited availability of effective treatment. Immunotherapy has emerged as a novel treatment approach…
Read MoreEvaluation of first-line and salvage therapies for unresectable malignant mesothelioma: A systematic review and network meta-analysis
Critical Reviews in Oncology and Hematology 2024 April 26 [Link] Wei Zhuang, Lihui Liu, Boyang Sun, Hua Bai, Zhijie Wang, Jianchun Duan, Rui Wan, Zixiao Ma, Jia Zhong, Jie Wang Abstract Background: Randomized controlled trials (RCTs) of systemic therapies for unresectable malignant mesothelioma have reported conflicting results. It is crucial and urgent to find optimal…
Read MoreAdvances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights
Open Respiratory Archives 2024 April 5 [Link] Rafael López-Castro, Álvaro Fuentes-Martín, Andrea Medina Del Valle, Tania García Peña, José Soro García, Leticia López González, Ángel Cilleruelo Ramos Abstract MPM stands as a rare malignancy necessitating improved therapeutic strategies due to its limited treatment choices and unfavorable prognosis. The advent of immune checkpoint inhibitors has heralded…
Read MoreAdvances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights
Open Respiratory Archives 2024 April 5 [Link] Rafael López-Castro, Álvaro Fuentes-Martín, Andrea Medina Del Valle, Tania García Peña, José Soro García, Leticia López González, Ángel Cilleruelo Ramos Abstract MPM stands as a rare malignancy necessitating improved therapeutic strategies due to its limited treatment choices and unfavorable prognosis. The advent of immune checkpoint inhibitors has heralded…
Read More